E7090 + rifampin

E7090 + rifampin is the combination of E7090, a selective, orally available inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases (FGFR1, FGFR2, FGFR3), with rifampin, an antibiotic and potent inducer of cytochrome P450 enzymes, especially CYP3A4. E7090 (also known as tasurgratinib and TASFYGO) is being developed by Eisai for the treatment of cancers, particularly those with FGFR genetic aberrations such as gene fusions, mutations, or amplifications. It acts by inhibiting FGFR-mediated signaling, thereby impeding tumor cell proliferation, survival, and angiogenesis[1][2][3][4][6][7]. Rifampin is a widely used antibacterial agent, commonly for tuberculosis, and is a strong inducer of hepatic microsomal enzymes, thus often studied for drug-drug interaction effects—its co-administration with E7090 may be intended to assess the impact of CYP3A4 induction on E7090's pharmacokinetics. There is no approved product combining these two agents as a fixed combination for therapeutic purposes; instead, this combination is studied for pharmacokinetic or potential interaction purposes.

Brand names

TASFYGO

Other names

tasurgratinibrifampicin